Shandong Lukang Pharmaceutical Co., Ltd. (600789.SS) is a China-based pharmaceutical company engaged in the research, development, manufacture, and sale of pharmaceutical products and intermediates. The company produces a range of active pharmaceutical ingredients (APIs) and finished dosage forms, including penicillin antibiotics such as amoxicillin, ampicillin, and 6-APA; cephalosporin antibiotics like cefazolin, cefotaxime, and cefuroxime; cardiovascular drugs; anti-infectives; and biochemical products, offered under its own brands and through contract manufacturing services. It operates primarily in the pharmaceutical industry, serving domestic hospitals, distributors, and international markets in Asia, Europe, and North America, with manufacturing facilities concentrated in Shandong province.
Founded in 1966 and headquartered in Rizhao, Shandong province, the company maintains subsidiaries focused on API production, formulation drugs, and pharmaceutical intermediates, with no disclosed parent company. Shandong Lukang Pharmaceutical expanded its operations through strategic investments in production capacity and quality compliance to meet global standards such as GMP and FDA requirements. No major acquisitions, funding rounds, partnerships, new product launches, or reorganizations have been publicly reported in the last 1-2 years as of December 2025.